§1 · The Entry at a Glance
A molecule built like a fortress, acting like a teacher
Bromantane belongs to the 2-aminoadamantane family — the same diamondoid cage lineage as amantadine, rimantadine and memantine — but it was engineered for a different purpose. Where classic psychostimulants force monoamines out of their stores and leave the system overdrawn, bromantane works upstream: it induces the expression of tyrosine hydroxylase and DOPA-decarboxylase, the enzymes that manufacture dopamine from scratch. The Russian pharmacologists who created it placed it in a class of their own making — the actoprotectors, defined as preparations that enhance the body's stability against physical loads without increasing oxygen consumption or heat production. The effect is activation without exhaustion: no crash when it wears off.
IUPAC : N-(4-bromophenyl)adamantan-2-amine
FORMULA : C₁₆H₂₀BrN · molar mass 306.24 g/mol
CAS : 87913-26-6 · PubChem CID 4660557
CLASS : actoprotector (synthetic adaptogen) · 2-aminoadamantane family
SMILES : C1C2CC3CC1CC(C2)C3NC4=CC=C(C=C4)Br
RU LABEL : Ladasten 50 mg tablets · manufacturer Lekko CJSC
PK (label): oral bioavailability ~42% · Tmax 2.75 h (women) / 4.0 h (men)
highly lipophilic · main metabolite 6β-hydroxybromantane
metabolites detectable in urine for 2+ weeks
§2 · Precision of Terms
What bromantane is — and what it is not
Accuracy matters more here than enthusiasm, because bromantane attracts myths. Three corrections frame this monograph:
- It is not a urea derivative. Bromantane is frequently misdescribed that way in marketing copy; the verified structure is an adamantane-derived secondary amine — an adamantane cage joined through nitrogen to a brominated phenyl ring.
- It is not a classic stimulant. Microdialysis shows increased striatal dopamine release and metabolism, yet monoamine-reuptake inhibition in vitro requires concentrations (50–500 µM) with no clinical relevance. Its action is genomic — transcriptional activation of dopamine-synthesis enzymes — and the molecular trigger upstream of that gene expression remains unknown.
- It was never a cosmonaut drug. The space-programme actoprotector was bemitil (Metaprot); no source ties bromantane itself to spaceflight. The cosmonaut story is a common embellishment that conflates the two compounds, and this monograph declines to repeat it.
§3 · Evidence Landscape
Where the documented effects stand
Every claim in this monograph carries its evidence tier. Human efficacy rests on two Russian clinical trials; endurance, heat and immune findings rest on animal and review-level evidence, and are labelled as such.
| Benefit area | Finding | Evidence tier |
|---|---|---|
| Anti-fatigue / anti-asthenia | 728-patient, 28-centre trial: effect from day 3, persisting one month after treatment; 76.0–90.8% responder rates | Clinical |
| Neurasthenia, anxiolytic without sedation | Placebo-controlled trial: superior symptom reduction; no hypno-sedative action; no withdrawal on discontinuation | Clinical |
| Physical endurance & work capacity | Exceeded amphetamine's effect 1.3–1.6× in mouse swimming and rat treadmill tests | Animal |
| Performance in heat & hypoxia | Thermoprotective effects during overheating; recovery support under hypoxia per the actoprotector review | Animal Review |
| Immune support | B-cell increases after a single dose; T-cell normalisation in chronically stressed mice; lower IL-6/IL-17 in an anxiety-depression model | Animal |
| No dependence, tolerance or withdrawal | Consistent across the clinical trials and chronic animal administration | Clinical Animal |
The full map — including mental performance, motivation and recovery — is on the Documented Effects page, each entry with its tier and source.
§4 · The Core Idea
Upregulation, not stimulation
A single oral dose of bromantane induces transcription of the tyrosine-hydroxylase and DOPA-decarboxylase genes in the striatum and hypothalamus; the resulting accumulation of L-DOPA and dopamine tracks the transcriptional activation — de novo synthesis, not released reserves. Later work confirmed TH upregulation across the VTA, nucleus accumbens, hypothalamus, striatum and hippocampus, and showed bromantane converting short-term hippocampal potentiation into long-term potentiation dependent on protein synthesis and D1/D5 receptors. An epigenetic correlate — demethylation of the TH gene promoter — has been reported. The story, in full, is on the Mechanism of Action page.
§5 · Provenance
A Russian creation, honoured as such
Bromantane emerged in the 1980s from the Zakusov Institute of Pharmacology in Moscow, inside a research tradition launched in the 1970s by Professor Vladimir Vinogradov's actoprotector programme — the same school that first produced bemitil. Russian science created this compound; Panacea Bio Chem studies it, credits its makers, and claims nothing of its invention. The honest chronicle — including the 1996 Atlanta Olympics detection and the ~2009 Ladasten approval — is told on The Actoprotector Story.
§6 · From the Research Director
Why this molecule holds our attention
“An actoprotector does not whip the horse — it feeds the engine. Bromantane interests me precisely because it works upstream, at the expression of the enzymes that build dopamine, rather than downstream where stimulants spend the system's reserves. The Russian school mapped that territory with rigour; our task at Panacea is to re-examine it with modern instrumentation, and to stay exact about what the data can and cannot carry.”
Bogdan Dicoias — Biochemist · AAC Designer · Panacea Bio Chem Ltd
§7 · Ongoing Investigation
The Panacea research angle
Panacea Bio Chem is investigating bromantane within its molecular-performance and formulation research programme: analytical characterisation of the molecule, the actoprotector mechanism literature, and formulation science relevant to adamantane-class compounds. This is an ongoing investigation; no internal results are asserted on this site, and nothing here should be read as a completed study. What these pages present is the published record — two human trials, a body of animal work, and one peer-reviewed English review — with its tiers marked. As the programme produces findings that survive scrutiny, they will be added to the Research & Sources page.
§8 · Frequently Asked
Frequently asked
Is bromantane a stimulant?
No. Bromantane is an actoprotector — a synthetic adaptogen of non-exhaustive action. Rather than forcing dopamine release the way psychostimulants do, it upregulates expression of tyrosine hydroxylase, the rate-limiting enzyme of dopamine synthesis, so the body produces more of its own dopamine. Clinical trials report no hyperstimulation and no withdrawal after discontinuation.
What is bromantane's regulatory status?
In Russia bromantane is an approved prescription medicine (Ladasten, 50 mg tablets) for asthenic disorders. In the United States it is unscheduled but not FDA-approved, and no EU or UK marketing authorisation has been identified; elsewhere it is treated as a research compound. It has been prohibited in sport since 1997.
Who developed bromantane?
Bromantane was created in the 1980s at the Zakusov Institute of Pharmacology of the USSR Academy of Medical Sciences in Moscow, within the Soviet actoprotector research tradition that began with Professor Vladimir Vinogradov's programme in the 1970s. Panacea Bio Chem honours that origin and investigates the compound's future; it does not claim its invention.
Ten questions, answered with the same discipline, on the Questions page.
§9 · Current Literature
Trending in the literature
Recent developments in the field — refreshed 2026-09-08 by Panacea Bio Chem.
- Plant Adaptogens-History and Future Perspectives — PubMed, 2021 Aug 20
- The pharmacology of actoprotectors: practical application for improvement of mental and physical performance — PubMed, 2012 Sep
- Toxic effect of single treatment with bromantane on neurological status of experimental animals — PubMed, 2002 Apr
- [Complex evaluation of the effect of bromantane on animal behavior] — PubMed, 2001 Sep-Oct
§10 · Citations
References for this page
- Oliynyk S, Oh S. The pharmacology of actoprotectors. Biomol Ther (Seoul). 2012;20(5):446-56. PMC3762282 · PMID 24009833
- Vakhitova IuV, Iamidanov RS, Seredinin SB. Ladasten induces the expression of genes regulating dopamine biosynthesis. Eksp Klin Farmakol. 2004;67(4):7-11. PMID 15500036
- Mikhaylova M, Vakhitova JV, Yamidanov RS, et al. Ladasten, dopaminergic neurotransmission and hippocampal plasticity. Neuropharmacology. 2007;53(5):601-8. PMID 17854844
- Neznamov GG, Siuniakov SA, Teleshova SE, et al. Ladasten in neurasthenia: placebo-controlled study. Zh Nevrol Psikhiatr Korsakova. 2009;109(5):20-6. PMID 19491814
- Voznesenskaia TG, Fokina NM, Iakhno NN. Multicenter study of ladasten in asthenic disorders (728 patients). Zh Nevrol Psikhiatr Korsakova. 2010;110(5 Pt 1):17-26. PMID 21322821
- Burnat P, Payen A, Le Brumant-Payen C, Hugon M, Ceppa F. Bromontan, a new doping agent. Lancet. 1997;350(9082):963-4. PMID 9314900
- Bromantane — compound record. PubChem CID 4660557.
The complete citation set, with evidence-tier notes, lives on Research & Sources.
